益肾升白贴联合穴位注射治疗放化疗所致骨髓抑制的疗效观察

Effect of Yishen Shengbai Plaster Combined with Acupoint Injection on Myelosuppression Caused by Chemoradiotherapy

目的观察益肾升白贴联合穴位注射地塞米松治疗恶性肿瘤放化疗所致骨髓抑制的疗效及副作用。方法将101例恶性肿瘤放化疗后发生骨髓抑制的病人随机分成3组,35例采用益肾升白贴联合穴位注射地塞米松治疗,35例仅采用穴位注射地塞米松治疗作为对照组1组,31例以重组人粒细胞集落刺激因子皮下注射治疗作为对照组2组。观察骨髓功能恢复情况及用药的不良反应。结果3组病人骨髓功能恢复时间及总有效率无统计学差异(P>0.05),3组病人经治疗后再程放化疗,骨髓功能分级有统计学意义(P<0.05),益肾升白贴联合穴位注射地塞米松治疗组再程放化期间,仍对骨髓功能有显著保护作用。3组病人均无特殊不良反应。结论益肾升白贴联合穴位注射地塞米松治疗恶性肿瘤放化疗后骨髓抑制安全、有效,且对骨髓功能保护时间长,无明显不良反应,值得临床推广使用。

Objective To observe the efficacy and side Yishen Shengbai Plaster combined with acupoint injection on myelosuppression caused by chemoradiotherapy in malignant tumors.Methods Chemotherapy were randomly divided into three groups,35 patients were treated with combined acupoint injection dexamethasone,35 patients with only acupoint injection dexamethasone treatment as a control group 1,31 patients with recombinant human granulocyte colony-stimulating factor subcutaneous injection treatment as a control group 2.Bone marrow function recovery and drug adverse effects were observed.Results There was no statistical difference in recovery time and total response rate(P>0.05).The three groups underwent chemoradiotherapy and bone marrow function was significant(P<0.05)in the treatment group of dexamethasone injection.None of the three groups of patients had special adverse effects.Conclusion Bone marrow suppression combined with acupoint injection is safe and effective,and has no obvious adverse effects against bone marrow function,which is worthy of clinical application.